L'Oréal has submitted to the shareholders of Holding STRP (Société des Thermes de La Roche-Posay) an offer for the acquisition of all the shares of their company.
Created in 1921, Société des Thermes de La Roche-Posay is the first thermal station in Europe exclusively dedicated to treating dermatological diseases. The thermal water of La Roche-Posay has therapeutic anti-inflammatory, healing and soothing properties to treat skin diseases (eczema, psoriasis, burn scars and cutaneous side effects of cancer treatments). In 2017, more than 7,500 patients have benefited from the thermal activity, generating €3.6 million of sales.
Laetitia Toupet, international general manager of La Roche-Posay, said: "this acquisition project will enable us to sustain and reinforce the dermatologic position of La Roche-Posay by developing the existing indications and making the thermal station a flagship for the brand."
Recommended by over 90,000 dermatologists worldwide, La Roche-Posay creates skincare for sensitive skin, formulated with thermal water. It was the first dermo-cosmetic brand worldwide, with key product ranges like: Lipikar (dry skin), Anthélios (photoprotection), Effaclar (acne), Tolériane (sensitive skin) and Cicaplast (skin repair).
This project will be submitted for consultation to employee representatives and should be completed in the following months.
